Last €22.41 EUR
Change Today +0.198 / 0.89%
Volume 65.8K
As of 6:13 AM 03/3/15 All times are local (Market data is delayed by at least 15 minutes).

qiagen n.v. (QIA) Snapshot

Open
€22.29
Previous Close
€22.21
Day High
€22.49
Day Low
€22.20
52 Week High
03/2/15 - €22.68
52 Week Low
04/15/14 - €14.03
Market Cap
5.4B
Average Volume 10 Days
368.7K
EPS TTM
€0.68
Shares Outstanding
239.7M
EX-Date
--
P/E TM
36.7x
Dividend
--
Dividend Yield
--
Current Stock Chart for QIAGEN N.V. (QIA)

qiagen n.v. (QIA) Related Businessweek News

No Related Businessweek News Found

qiagen n.v. (QIA) Details

QIAGEN N.V. provides sample and assay technologies worldwide. It offers approximately consumable products, such as sample and assay kits, and automated instrumentation systems that empower customers to transform raw biological samples into molecular information. The company’s consumable products are used for plasmid deoxyribonucleic acid (DNA) purification, and ribonucleic acid purification and stabilization; genomic and viral nucleic acid purification; nucleic acid transfection; polymerase chain reaction (PCR) amplification; reverse transcription; DNA cleanup after PCR and sequencing; and DNA cloning and protein purification. The company sells the digene HC2 HPV Test for high-risk strains of the human papillomavirus. It also offers co-development services for companion diagnostics, technology licensing and patent sales services, and custom services, including whole genome amplification, DNA sequencing, and non-cGMP DNA production on a contract basis. In addition, the company provides instrumentation systems that automate the use of sample and assay technologies into solutions for a range of laboratory needs enabling customers to perform nucleic acid sample preparation, assay setup, and target detection, as well as workflow solutions. Its automated systems include QIAsymphony, a modular system; Rotor-Gene Q, a rotary real-time PCR cycler system; PyroMark, a high-resolution detection platform; QIAcube, a sample processing instrument; QIAxcel for nucleic acid separation; and ESE-Quant tube scanners. The company serves molecular diagnostics laboratories; applied testing customers; pharmaceutical research and development groups, and academic researchers. It has a collaboration agreement with AstraZeneca PLC to co-develop and commercialize liquid biopsy-based companion diagnostic; and Astellas Pharma Inc. to develop and commercialize companion diagnostics for use in cancer and other diseases. QIAGEN N.V. was founded in 1986 and is headquartered in Venlo, the Netherlands.

4,300 Employees
Last Reported Date: 01/28/15
Founded in 1986

qiagen n.v. (QIA) Top Compensated Officers

Chairman of Management Board, Chief Executive...
Total Annual Compensation: $1.5M
Chief Financial Officer, Managing Director an...
Total Annual Compensation: $639.5K
Compensation as of Fiscal Year 2013.

qiagen n.v. (QIA) Key Developments

Qiagen NV Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2014; Provides Earnings Guidance for the First Quarter and Full Year of 2015

Qiagen NV reported earnings results for the fourth quarter and full year ended December 31, 2014. For the quarter, the company reported adjusted net sales of $360.8 million compared to $362.6 million a year ago. Adjusted operating income was $71.6 million compared to $95.3 million a year ago. Adjusted net income was $60.4 million compared to $79.8 million a year ago. Adjusted diluted EPS was $0.25 compared to $0.33 a year ago. Operating income was $20.6 million compared to $34.0 million in the same period of 2013, with one-time charges taken in both periods related to acquisitions and restructuring initiatives. For the full year, the company reported adjusted net sales of $1,346.2 million compared to $1,306.3 million a year ago. Adjusted operating income was $312.5 million compared to $318.1 million a year ago. Adjusted net income was $241.1 million compared to $246.3 million a year ago. Adjusted diluted EPS was $1.00 compared to $1.02 a year ago. Operating income was $160.8 million compared to $63.3 million in 2013, with one-time charges taken in both periods for acquisitions and restructuring initiatives. Net income attributable to owners of the company in 2014 was $116.6 million, or $0.48 per diluted share compared to $69.1 million or $0.29 per share in 2013. Net cash provided by operating activities in 2014 rose to $288.0 million from $259.0 million in 2013, with free cash flow increasing to $201.4 million in 2014 compared to $174.5 million in 2013. For the full year of 2015, the company expects to deliver higher adjusted net sales and adjusted earnings in 2015 at constant exchange rates (CER) with above-market sales growth from the current core portfolio. Adjusted net sales are expected to rise approximately 4% CER, as growth of about 7-8% CER in the core portfolio. Adjusted diluted earnings per share (EPS) are expected to be approximately $1.16 to $1.18 CER compared to $1.00 in 2014. For the first quarter of 2015, the company expects adjusted net sales growth of approximately 2% CER, which includes approximately 5-6 percentage points of headwind from U.S. HPV sales, and adjusted EPS of approximately $0.22 to $0.23 CER.

QIAGEN Introduces QuantiFERON Monitor® for Tracking Immune Function in Solid Organ Transplant Patients and for Research Into Other Applications

Qiagen NV announced the commercial launch of QuantiFERON Monitor® (QFM®), a novel diagnostic for monitoring immune function. QIAGEN is launching QuantiFERON Monitor in Europe as a CE-marked in-vitro diagnostic. Primary applications include monitoring of immune function in solid organ transplant recipients. In North America and other markets, QFM is available for research use as an accurate marker of immune function in studies of immunosuppressive conditions, immune modulating therapies and recovery following transplantation. More than 100,000 patients a year worldwide undergo solid organ transplant surgery. QFM measures the cell-mediated immune response and can provide important information on the strength of the immune system in the immunosuppressed solid organ transplant population. The test thereby targets an important medical need of physicians who need to assess patients' risk for both organ rejection and infections in order to determine the right dosage of immunosuppressive drugs. Currently, best practice in assessing immune reactivity is to monitor levels of those drugs. However, there are no standard drug regimens applied to all patients. As an estimated 40-70% of deaths following transplant surgery are attributable to issues with immunosuppression or immunosuppressants, the Food and Drug Administration (FDA) has recommended that drug levels alone should not be used to adjust drug dosing. QuantiFERON Monitor addresses the critical unmet medical need with a range of novel characteristics that hold promise for clinicians and researchers: QFM uses a combination of stimulants that specifically target different cell types involved in both the innate and adaptive immune systems to detect cell-mediated immune response, thereby providing qualitative and quantitative measurement of cell-mediated immune function. Clinical studies are underway to investigate; QFM's utility in transplantation for multiple organs (heart, lung, liver and kidney); QuantiFERON Monitor has the potential to allow clinicians to guide preventive treatment decisions by accurately predicting the risks for organ rejection and infections - and to reduce the dosing of costly and potentially toxic drugs during recovery; QFM leverages QuantiFERON technology - demonstrated in global use with QIAGEN's QuantiFERON-TB® Gold, QuantiFERON-TB® Gold Plus and QuantiFERON-CMV® - to support standardized, rapid and cost-effective testing. QuantiFERON Monitor applies this robust technology to monitoring the immune system and complements QIAGEN's transplant portfolio; QuantiFERON Monitor holds potential for application in monitoring immune response for other conditions, including inflammatory bowel disease, HIV, cancer and immunotherapy. QIAGEN expects research in these fields to further explore the clinical utility of QFM.

Qiagen NV, Q4 2014 Earnings Call, Jan 29, 2015

Qiagen NV, Q4 2014 Earnings Call, Jan 29, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
QIA:GR €22.41 EUR +0.198

QIA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Bio-Rad Laboratories Inc $132.47 USD +5.29
BioMerieux €97.13 EUR +0.57
Cepheid $57.28 USD +0.44
Myriad Genetics Inc $33.49 USD -0.58
PerkinElmer Inc $47.15 USD +0.15
View Industry Companies
 

Industry Analysis

QIA

Industry Average

Valuation QIA Industry Range
Price/Earnings 52.1x
Price/Sales 4.5x
Price/Book 2.2x
Price/Cash Flow 39.2x
TEV/Sales 3.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact QIAGEN N.V., please visit www.qiagen.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.